Acer Therapeutics Inc. (ACER): Price and Financial Metrics


Acer Therapeutics Inc. (ACER): $1.35

0.01 (+0.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACER POWR Grades

  • Sentiment is the dimension where ACER ranks best; there it ranks ahead of 70.71% of US stocks.
  • ACER's strongest trending metric is Value; it's been moving down over the last 33 days.
  • ACER's current lowest rank is in the Stability metric (where it is better than 9.18% of US stocks).

ACER Stock Summary

  • ACER's price/sales ratio is 63.33; that's higher than the P/S ratio of 96.76% of US stocks.
  • ACER's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 2.4% of US stocks.
  • As for revenue growth, note that ACER's revenue has grown -91% over the past 12 months; that beats the revenue growth of just 1.27% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ACER THERAPEUTICS INC, a group of peers worth examining would be VTVT, AERI, NAVB, MIMO, and TTOO.
  • Visit ACER's SEC page to see the company's official filings. To visit the company's web site, go to www.acertx.com.

ACER Valuation Summary

  • ACER's price/sales ratio is 59.4; this is 3026.32% higher than that of the median Healthcare stock.
  • Over the past 201 months, ACER's EV/EBIT ratio has gone down 0.

Below are key valuation metrics over time for ACER.

Stock Date P/S P/B P/E EV/EBIT
ACER 2022-09-23 59.4 -2.4 -1.1 -0.8
ACER 2022-09-22 60.3 -2.5 -1.1 -0.8
ACER 2022-09-21 58.9 -2.4 -1.1 -0.8
ACER 2022-09-20 59.7 -2.4 -1.1 -0.8
ACER 2022-09-19 64.2 -2.6 -1.2 -0.9
ACER 2022-09-16 63.3 -2.6 -1.2 -0.9

ACER Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -205.23%.
  • The 4 year revenue growth rate now stands at -100%.
  • Its 2 year net cashflow from operations growth rate is now at 75.22%.
Over the past 52 months, ACER's revenue has gone up $360,000.

The table below shows ACER's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.36 -22.24394 -19.53969
2022-03-31 0.36 -6.153168 -19.94169
2021-12-31 1.26 -0.134909 -15.37399
2021-09-30 0.9 -2.594543 -17.19103
2021-06-30 3.998133 0.915877 -16.90639
2021-03-31 3.998133 -8.952031 -19.44992

ACER Price Target

For more insight on analysts targets of ACER, see our ACER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.75 (Moderate Buy)

ACER Stock Price Chart Interactive Chart >

Price chart for ACER

ACER Price/Volume Stats

Current price $1.35 52-week high $3.77
Prev. close $1.34 52-week low $1.16
Day low $1.31 Volume 7,446
Day high $1.36 Avg. volume 231,593
50-day MA $1.45 Dividend yield N/A
200-day MA $2.01 Market Cap 21.52M

Acer Therapeutics Inc. (ACER) Company Bio


Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.


ACER Latest News Stream


Event/Time News Detail
Loading, please wait...

ACER Latest Social Stream


Loading social stream, please wait...

View Full ACER Social Stream

Latest ACER News From Around the Web

Below are the latest news stories about ACER THERAPEUTICS INC that investors may wish to consider to help them evaluate ACER as an investment opportunity.

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

Yahoo | September 15, 2022

Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.

Yahoo | September 13, 2022

Acer Therapeutics to Participate in August and September 2022 Investor Conferences

NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually present at, and participate in, the upcoming Gilmartin Group Emerging Growth Company Showcase and H.C. Wainwright 24th Annual Global Investment Conference. Conference:

Yahoo | August 23, 2022

H.C. Wainwright Sticks to Its Buy Rating for Acer Therapeutics (ACER)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Acer Therapeutics (ACER - Research Report) today and set a price target of $12.00. The company's shares opened today at $1.44.Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Achieve Life Sciences, and Seres Therapeutics. According to TipRanks, Bernardino has an average return of 25.7% and a 36.38% success rate on recommended stocks. Currently, the analyst consensus on Acer Therapeutics is a Moderate Buy with an average price target of $12.00.See the top stocks recommended by analysts >>The company has a one-year high of $3.77 and a one-year low of $1.16.

Austin Angelo on TipRanks | August 22, 2022

Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update

NEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. “I am very pleased with our team’s quick turnaround of our New Drug Application (NDA) resubmission following receipt

Yahoo | August 15, 2022

Read More 'ACER' Stories Here

ACER Price Returns

1-mo -10.60%
3-mo -0.74%
6-mo -53.45%
1-year -47.27%
3-year -59.09%
5-year -89.61%
YTD -40.79%
2021 -12.98%
2020 -34.66%
2019 -80.07%
2018 45.27%
2017 45.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6478 seconds.